10/06/2016
Progress Report: Muneesh Tewari, MD, Ph.D
Investigator: Muneesh Tewari, MD, PhD–Assistant Member, Fred Hutchinson Cancer Research Center, University of Washington Exosomal RNAs as Serum Prostate Cancer Biomarkers—Personalized Treatment and Better Prognostic Indicators May Become Reality Through MicroRNA Tumor Profiling Dr. Tewari and colleagues have discovered that cancer cells shed tiny vesicles from their membrane, much like. Read More
10/06/2016
Progress Report: Pier Paolo Pandolfi, MD, Ph.D
Investigator: Pier Paolo Pandolfi, MD, PhD–George C. Reisman Professor of Medicine, Harvard Medical School, Director, Cancer Genetics Program, Associate Director, Cancer Center Beth Israel Deaconess Medical Center Pro-Senescence Therapy for Prostate Cancer The human body has a number of mechanisms in place to protect against cancer growth and survival. One. Read More
10/06/2016
Progress Report: David Nanus, MD
Investigator: David Nanus, MD–Professor of Medicine, Professor of Urology, Mark W. Pasmantier Professor of Hematology and Oncology in Medicine at Weill Cornell Medical College Circulating Tumor Cell Biomarker Discovery of Taxotere Response Docetaxel (Taxotere) chemotherapy is the standard first line treatment for patients with castrate resistant prostate cancer (CRPC). Data. Read More
10/06/2016
Progress Report: Towia Libermann, Ph.D; Alan Rigby, Ph.D
Co-Investigator: Towia Libermann, PhD–Associate Professor, Medicine, Director, Genomics and Proteomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Director, Dana Farber Cancer Institute Cancer Proteomics Core, Harvard Medical School Co-Investigator: Alan Rigby, PhD–Assistant Professor, Medicine, Director, Program in Drug Discovery and Target Validation, Beth Israel Deaconess Medical Center, Harvard Medical. Read More
10/06/2016
Progress Report: Karen Knudsen, Ph.D; Adam Dicker, MD, Ph.D
Co-Investigator: Karen Knudsen, PhD–Associate Professor, Department of Cancer Biology and Urology at the Kimmel Cancer Center, Thomas Jefferson University Co-Investigator: Adam Dicker, MD, PhD–Professor, Chairman of Radiation Oncology, Director of Christine Baxter Research Laboratory for Experimental Cancer Therapies, Co-Director Radiation Research and Translational Biology Program at the Kimmel Cancer Center,. Read More
10/06/2016
Progress Report: Shelton Earp, MD; Joseph Desimone, Ph.D
Co-Investigator: Shelton Earp, MD– Director and Lineberger Professor, Professor of Medicine and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill Co-Investigator: Joseph DeSimone, PhD–Chancellor’s Eminent Professor of Chemistry, University of North Carolina-Chapel Hill, William R. Kenan, Jr. Distinguished Professor of Chemical Engineering, North Carolina State University Application of. Read More
10/06/2016
Progress Report: Cory Abate-Shen, Ph.D
Investigator: Cory Abate-Shen, PhD–Professor of Urology and Pathology, Director of Research, Department of Urology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Identification of Oncogenic Pathways Conserved from Mouse to Man Dr. Abate-Shen’s research goals are to identify new molecules that drive prostate cancer progression. Her approach to this. Read More
10/05/2016
Questions to Ask Before Starting Chemotherapy
Since my PSA is rising again, do we discontinue the androgen deprivation therapy ("hormone therapy")? Why or why not? Are there additional hormone therapy approaches that we should explore? Should I get a bone scan or CT scan to determine if the cancer has spread to my bones? What will. Read More
10/03/2016
Questions to Ask your Doctor: Recurrence of Prostate Cancer
When it is caught early, prostate cancer is usually curable. However, some men may see a return of their cancer, which can occur many years later. Generally, this will be noticed because of a rising PSA, and your doctor may recommend more treatment. Here are a few questions to ask. Read More
10/03/2016
Questions to Ask your Doctor: Advanced Stage
If you have been diagnosed with advanced stage prostate cancer (cancer that has metastasized beyond the prostate), your cancer may not be curable at this time, but treatments may slow the progression of the disease. A goal of oncology is for patients to "be there for the cure." You want to. Read More